Newborn Screening Market Expected to Growth of 6-8% from 2022 to 2027

BRUSSELS - May 23, 2023 - PRLog -- Newborn screening (https://meditechinsights.com/newborn-screening-market/) aims to detect infants at risk of genetic, hormonal and metabolic conditions.These tests are most commonly performed for conditions that are not clinically evident in the neonatal period but are likely to be treatable with early intervention.

Growing Population, Rising levels of birth defects, and favourable government initiatives are some of the major drivers for the growth of the newborn screening market

Global population projected to grow to 9.7 billion people by 2050 from 8 billion in 2022 and improving access to primary care (evidenced by significant global improvements in life expectancy) are major driving factors in the growth of the newborn screening market.
As per CDC, birth defects affect one in every 33 babies (about 3% of all babies) born in the United States each year. Heart problems, neural tube defects, and Down syndrome are among the most frequent serious birth disorders.

Growing use of next-generation sequencing (NGS) in developed nations is expected to fuel the newborn screening markets

The cost of sequencing whole exomes has fallen dramatically since its invention and continues to decrease – in the US, bioinformatics companies can provide sequencing for ~$500-$900. Pilot studies are being conducted

Organic and Inorganic Growth Strategies Adopted by Players to Establish Their Foothold in the Newborn Screening Market

• In August 2022, Perkin Elmer entered into a definitive agreement with New Mountain Capital, L.L.C. to sell off its assets for a total compensation of $2.45 Bn
• In August 2022, Triviton Healthcare opened a new R&D and manufacturing facility for chemical-based assays in India. The new center will manufacture >300 million RT-PCR kits and >100 million for ELISA, CLIA, NBS

China is expected to hold the largest share of the Newborn Screening market – followed by North America

9.56 million babies were born in China in 2022. Approximately 93% of newborns reported to undergo screening in China. The penetration of newborn screening in China is to grow in the future years due to government initiatives, growing number of newborn screening centers and establishment of well-developed newborn screening network system. By  end of 2018, there were ~238 newborn screening centers in the China mainland screening rates exceeding 97.5%.

The market is marked by the presence of key players such as SCIEX, Agilent Technologies Inc., Bio-Rad Laboratories Inc., Covidien Plc, GE Healthcare, PerkinElmer, Inc., Masimo Corporation, Natus Medical Incorporated, Trivitron Healthcare, Waters Corporation, Labsystems Diagnostics Oy, LifeCell International Pvt.Ltd, Archer DX.

Get Detailed Insights on Newborn screening Market @ https://meditechinsights.com/newborn-screening-market/